Pregabalin - Revision history

Zeki at 05:32, 5 September 2024

2024-09-05T05:32:29Z

← Older revision		Revision as of 01:32, 5 September 2024
Line 1:		Line 1:
	[[Category: Drugs]][[Category:Seizures]]		[[Category: Drugs]][[Category: Anticonvulsant]] [[Category:Seizures]]

			[[:Category: Anticonvulsant \| '''Anticonvulsant''']]

	'''Pregabalin'''(中文: [[普瑞巴林]])is an anticonvulsant medication:		'''Pregabalin'''(中文: [[普瑞巴林]])is an anticonvulsant medication:
	*Peripheral and central neuropathic pain		*Peripheral and central neuropathic pain

Helen: /* Drug Management */

2020-10-12T08:03:43Z

Drug Management

← Older revision		Revision as of 04:03, 12 October 2020
Line 150:		Line 150:

	==Drug Management==		==Drug Management==
	~~'''~~Monitoring		===Monitoring===
	*recognize signs of blood, liver, or skin toxicity. Seek immediate medical attention if symptoms such as fever, sore throat, rash, blistering, mouth ulcers, bruising or bleeding develop.		*recognize signs of blood, liver, or skin toxicity. Seek immediate medical attention if symptoms such as fever, sore throat, rash, blistering, mouth ulcers, bruising or bleeding develop.
	*Patients with heart failure should be weighed regularly to detect fluid retention.		*Patients with heart failure should be weighed regularly to detect fluid retention.
Line 156:		Line 156:
	*changes in mood, the development or worsening depression, and/or any thoughts or behavior of suicide.		*changes in mood, the development or worsening depression, and/or any thoughts or behavior of suicide.

	~~'''~~Drug interaction		===Drug interaction===
	No interactions have been demonstration ''in vivo.		No interactions have been demonstration ''in vivo.

	~~'''~~Caution		===Caution===
	*Avoid abrupt withdrawal		*Avoid abrupt withdrawal
	**Severe congestive heart failure		*Severe congestive heart failure
	*Conditions that may precipitate encephalopathy		*Conditions that may precipitate encephalopathy

	~~'''~~Renal impairment		===Renal impairment===
	Reduced doses according to creatinine clearance:		Reduced doses according to creatinine clearance:
	*If creatinine clearance 30 to 60 ml/minute: 75 mg daily and max. dose 300mg daily in 2 or 3 divided doses		*If creatinine clearance 30 to 60 ml/minute: 75 mg daily and max. dose 300mg daily in 2 or 3 divided doses
Line 171:		Line 171:
	*Haemodialysis patients should receive in addition to the daily dose a supplementary dose of 25 to 100 mg immediately after each 4-hour haemodialysis session		*Haemodialysis patients should receive in addition to the daily dose a supplementary dose of 25 to 100 mg immediately after each 4-hour haemodialysis session

	~~'''~~Pregnancy		===Pregnancy===
	Women of child-bearing potential should discuss with a specialist the impact of both epilepsy, and its treatment, on the outcome of pregnancy. There is an increased risk of teratogenicity associated with the use of antiepileptic drug (especially if used during the first trimester)		Women of child-bearing potential should discuss with a specialist the impact of both epilepsy, and its treatment, on the outcome of pregnancy. There is an increased risk of teratogenicity associated with the use of antiepileptic drug (especially if used during the first trimester)

	~~'''~~Breast-feeding		===Breast-feeding===
	Use during breast feeding is not recommended.		Use during breast feeding is not recommended.

	~~'''~~Epilepsy and driving		===Epilepsy and driving===
	Driving by patients with epilepsy is generally regulated. Also, antiepileptic drugs may produce CNS-related adverse effects, including dizziness and drowsiness, that could impair a patient’s ability to drive a vehicle or operate machinery, particularly during the initial stages of therapy.		Driving by patients with epilepsy is generally regulated. Also, antiepileptic drugs may produce CNS-related adverse effects, including dizziness and drowsiness, that could impair a patient’s ability to drive a vehicle or operate machinery, particularly during the initial stages of therapy.


	== FAQ ==		== FAQ ==

Helen: /* Pharmacokinetics */

2020-10-12T08:01:25Z

Pharmacokinetics

← Older revision		Revision as of 04:01, 12 October 2020
Line 132:		Line 132:

	{\|class="wikitable"		{\|class="wikitable"
	!Oral bioavailability		!style="text-align: left"\| Oral bioavailability
	\|Pregabalin is rapidly absorbed after oral doses.		\|Pregabalin is rapidly absorbed after oral doses.
	\|-		\|-
	!Onset of action		!style="text-align: left"\| Onset of action
	\|Peak plasma concentrations occur within 1.5 hours.		\|Peak plasma concentrations occur within 1.5 hours.
	Steady state is achieved after 1 to 2 days.		Steady state is achieved after 1 to 2 days.
	\|-		\|-
	!Metabolism		!style="text-align: left"\| Metabolism
	\|Pregabalin undergoes negligible metabolism.		\|Pregabalin undergoes negligible metabolism.
	\|-		\|-
	!Elimination half-life		!style="text-align: left"\| Elimination half-life
	\|Gabapentin is eliminated renally in the urine as unchanged drug.		\|Gabapentin is eliminated renally in the urine as unchanged drug.
	The mean elimination half-life is 6.3 hours. Because of its short elimination half-life, pregabalin is administered 2 to 3 times per day to maintain therapeutic levels.		The mean elimination half-life is 6.3 hours. Because of its short elimination half-life, pregabalin is administered 2 to 3 times per day to maintain therapeutic levels.

Helen: /* Pharmacokinetics */

2020-10-12T08:01:04Z

Pharmacokinetics

← Older revision		Revision as of 04:01, 12 October 2020
Line 138:		Line 138:
	\|Peak plasma concentrations occur within 1.5 hours.		\|Peak plasma concentrations occur within 1.5 hours.
	Steady state is achieved after 1 to 2 days.		Steady state is achieved after 1 to 2 days.

	\|-		\|-
	!Metabolism		!Metabolism
Line 149:		Line 148:

	\|}		\|}


	==Drug Management==		==Drug Management==

Helen: /* Side Effects */

2020-10-12T08:00:33Z

Side Effects

← Older revision		Revision as of 04:00, 12 October 2020
Line 127:		Line 127:
	\|}		\|}

			When pregabalin is taken at high doses over a long period of time, addiction may occur.
	When pregabalin is taken at high doses over a long period of time, addiction may occur.


	==Pharmacokinetics==		==Pharmacokinetics==

Helen: /* Dosage */

2020-10-12T08:00:05Z

Dosage

← Older revision		Revision as of 04:00, 12 October 2020
Line 34:		Line 34:
	==Dosage==		==Dosage==

	~~'''Epilepsy~~
	{\|class="wikitable"		{\|class="wikitable"
	!style="text-align: left"\|By mouth		!style="text-align: left"\| Epilepsy
	\|the initial oral dose is 25 mg twice daily, increased at weekly intervals in steps of 50 mg daily to 300 mg daily in 2-3 divided doses, increased further if necessary after 7 days to max. 600 mg daily in 2-3 divided doses.		\|By mouth
	\|}

			the initial oral dose is 25 mg twice daily, increased at weekly intervals in steps of 50 mg daily to 300 mg daily in 2-3 divided doses, increased further if necessary after 7 days to max. 600 mg daily in 2-3 divided doses.
			\|-
			!style="text-align: left"\|Neuropathic Pain
			\|By mouth

	~~'''Neuropathic Pain~~		initially 150 mg daily in 2-3 divided doses, increased if necessary after 3-7 days to 300 mg daily in 2-3 divided doses, increased further if necessary after 7 days to max. 600 mg daily in 2-3 divided doses.

	~~{\|class="wikitable"~~
	~~!style="text-align: left"\|By mouth~~
	\|initially 150 mg daily in 2-3 divided doses, increased if necessary after 3-7 days to 300 mg daily in 2-3 divided doses, increased further if necessary after 7 days to max. 600 mg daily in 2-3 divided doses.
	\|}

	Alternatively, 300 mg 3 times daily on day 1, then increased according to response in steps of 300mg (in 3 divided doses) every 2-3 days up to max. 3.6 g daily.		Alternatively, 300 mg 3 times daily on day 1, then increased according to response in steps of 300mg (in 3 divided doses) every 2-3 days up to max. 3.6 g daily.
			\|-
			!style="text-align: left"\|Generalized anxiety disorder
			\|By mouth

			initially 150 mg daily in 2-3 divided doses, increased if necessary at weekly intervals in steps of 150 mg daily; max. 600 mg daily in 2-3 divided doses.

	~~'''Generalized anxiety disorder~~		As with other antiepileptics, withdrawal of prgabalin therapy or transition to or from another type of antiepileptic therapy should be made gradually to avoid precipitating an increase in seizure frequency.

	~~{\|class="wikitable"~~
	~~!style="text-align: left"\|By mouth~~
	~~\|initially 150 mg daily in 2-3 divided doses~~, ~~increased if necessary at weekly intervals in steps~~ of ~~150 mg daily; max. 600 mg daily~~ in ~~2-3 divided doses~~.
	\|}		\|}



	As with other antiepileptics, withdrawal of prgabalin therapy or transition to or from another type of antiepileptic therapy should be made gradually to avoid precipitating an increase in seizure frequency.


	==Side Effects==		==Side Effects==

Helen: /* Drug name */

2020-10-12T07:58:21Z

Drug name

← Older revision		Revision as of 03:58, 12 October 2020
Line 23:		Line 23:
	\|Pregabalin Capsule 25mg		\|Pregabalin Capsule 25mg
	\|PREG15		\|PREG15
			\|P1S1S3
			\|-
			\|Pregabalin Capsule 75mg
			\|PREG16
	\|P1S1S3		\|P1S1S3
	\|}		\|}

Helen at 02:46, 9 October 2020

2020-10-09T02:46:36Z

← Older revision		Revision as of 22:46, 8 October 2020
Line 1:		Line 1:
	[[Category: Drugs]][[Category:~~Anticonvulsant medication~~]]		[[Category: Drugs]][[Category:Seizures]]
	'''Pregabalin'''(中文: [[普瑞巴林]])is an anticonvulsant medication:		'''Pregabalin'''(中文: [[普瑞巴林]])is an anticonvulsant medication:
	*Peripheral and central neuropathic pain		*Peripheral and central neuropathic pain

Helen at 02:22, 8 October 2020

2020-10-08T02:22:19Z

@@ Line 1: / Line 1: @@
-[[Category: Drugs]]
+[[Category: Drugs]][[Category:Anticonvulsant medication]]
 ==Pronunciation==
 ===Pregabalin 150mg===
@@ Line 10: / Line 15: @@
 [[File:Pregabalin 50mg.mp3]]
+==Drug name==
 {| class="wikitable"
 !Generic Name 藥名
@@ Line 35: / Line 26: @@
 |}
+==Mechanism of Action==
 ==Dosage==

Helen at 02:54, 6 October 2020

2020-10-06T02:54:40Z

← Older revision		Revision as of 22:54, 5 October 2020
Line 166:		Line 166:

	==Drug Management==		==Drug Management==
	~~===~~Monitoring~~===~~		'''Monitoring
	*recognize signs of blood, liver, or skin toxicity. Seek immediate medical attention if symptoms such as fever, sore throat, rash, blistering, mouth ulcers, bruising or bleeding develop.		*recognize signs of blood, liver, or skin toxicity. Seek immediate medical attention if symptoms such as fever, sore throat, rash, blistering, mouth ulcers, bruising or bleeding develop.
	*Patients with heart failure should be weighed regularly to detect fluid retention.		*Patients with heart failure should be weighed regularly to detect fluid retention.
Line 172:		Line 172:
	*changes in mood, the development or worsening depression, and/or any thoughts or behavior of suicide.		*changes in mood, the development or worsening depression, and/or any thoughts or behavior of suicide.

	~~===~~Drug interaction~~===~~		'''Drug interaction
	No interactions have been demonstration ''in vivo.		No interactions have been demonstration ''in vivo.

	~~===~~Caution~~===~~		'''Caution
	*Avoid abrupt withdrawal		*Avoid abrupt withdrawal
	**Severe congestive heart failure		**Severe congestive heart failure
	*Conditions that may precipitate encephalopathy		*Conditions that may precipitate encephalopathy

	~~===~~Renal impairment~~===~~		'''Renal impairment
	Reduced doses according to creatinine clearance:		Reduced doses according to creatinine clearance:
	*If creatinine clearance 30 to 60 ml/minute: 75 mg daily and max. dose 300mg daily in 2 or 3 divided doses		*If creatinine clearance 30 to 60 ml/minute: 75 mg daily and max. dose 300mg daily in 2 or 3 divided doses
Line 187:		Line 187:
	*Haemodialysis patients should receive in addition to the daily dose a supplementary dose of 25 to 100 mg immediately after each 4-hour haemodialysis session		*Haemodialysis patients should receive in addition to the daily dose a supplementary dose of 25 to 100 mg immediately after each 4-hour haemodialysis session

	~~===~~Pregnancy~~===~~		'''Pregnancy
	Women of child-bearing potential should discuss with a specialist the impact of both epilepsy, and its treatment, on the outcome of pregnancy. There is an increased risk of teratogenicity associated with the use of antiepileptic drug (especially if used during the first trimester)		Women of child-bearing potential should discuss with a specialist the impact of both epilepsy, and its treatment, on the outcome of pregnancy. There is an increased risk of teratogenicity associated with the use of antiepileptic drug (especially if used during the first trimester)

	~~===~~Breast-feeding~~===~~		'''Breast-feeding
	Use during breast feeding is not recommended.		Use during breast feeding is not recommended.

	~~===~~Epilepsy and driving~~===~~		'''Epilepsy and driving
	Driving by patients with epilepsy is generally regulated. Also, antiepileptic drugs may produce CNS-related adverse effects, including dizziness and drowsiness, that could impair a patient’s ability to drive a vehicle or operate machinery, particularly during the initial stages of therapy.		Driving by patients with epilepsy is generally regulated. Also, antiepileptic drugs may produce CNS-related adverse effects, including dizziness and drowsiness, that could impair a patient’s ability to drive a vehicle or operate machinery, particularly during the initial stages of therapy.